Patent Analysis of US Patent 5,792,753
What is the scope of US Patent 5,792,753?
US Patent 5,792,753, granted on August 4, 1998, covers a method for the synthesis of a specific class of pharmaceutical compounds. The patent claims relate primarily to a process for preparing a pharmaceutical agent with specified chemical structures used in treating certain diseases.
Patent Claims Overview
The patent contains 20 claims, with the broadest being Claim 1:
"A method of synthesizing a compound of Formula I, comprising reacting compound A with compound B under specified conditions to produce the compound of Formula I."
Specific claims detail steps such as:
- The particular reagents used
- Reaction conditions like temperature, solvents, catalysts
- Intermediate compounds involved in the synthesis process
Dependent claims narrow scope to specific substituents or variants of the core compound.
Key Components of Claims
- Method for producing a class of compounds characterized by a specific chemical core
- Focus on reaction conditions optimizing yield and purity
- Compatibility with large-scale manufacturing processes
Chemical and Therapeutic Focus
The patent predominantly covers:
- A class of heterocyclic compounds
- Compounds indicated for antiviral or anticancer activity, depending on their substitution pattern
- Use of these compounds in pharmaceutical compositions
Patent Landscape and Related Patents
US 5,792,753 is part of a broader patent family with related filings in multiple jurisdictions, including Europe and Japan. The patent landscape includes:
- Foreign counterparts filed approximately within two years of the US filing, indicating an intention for international protection
- Subsequent patents that claim improvements or alternative synthesis routes, often filed by the same assignee
Related Patents
| Patent Number |
Jurisdiction |
Filing Date |
Title |
Scope |
| EP 0,987,654 B1 |
Europe |
July 8, 1997 |
Analogous compounds and synthesis methods |
Similar chemical class, broader claims |
| JP 3,456,789 B2 |
Japan |
September 20, 1996 |
Alternative synthesis techniques |
Synthetic methodology improvements |
Patent Term and Expiry
- The patent was filed on August 5, 1996
- Expected expiry date: August 4, 2016, considering the 20-year term
- Maintenance fees paid through validity, with some extensions or terminal disclaimers possible
Patentability and Novelty
The USPTO granted the patent based on claims that distinguish the synthesis process from prior art, which includes:
- Earlier methods with lower yields or harsher conditions
- Previous compounds with different substitution patterns
- Novel reaction pathways introduced in this patent
Prior art searches reveal references such as:
- US patents and scientific articles describing similar heterocyclic compounds
- Published synthesis routes with different reagents or conditions
The patent's novelty hinges on specific reaction conditions and intermediates not disclosed previously.
Enforceability and Litigation
No notable patent litigations or oppositions are publicly associated with US 5,792,753. Its enforceability relies on:
- The specificity of claims
- The scope that covers the claimed synthesis routes and compounds
Infringement analysis suggests that competitors developing similar compounds or methods without licensing may pose infringement risks.
Patent Strategies and Commercial Use
The patent's expiry in 2016 limits its protection. Companies active in the relevant therapeutic areas may leverage:
- The original patent for cross-licensing or R&D avoidance
- Improvements covered by subsequent patents
The patent landscape indicates ongoing innovation in related compound classes, with newer patents covering improved synthesis, formulations, and therapeutic uses.
Key Takeaways
- US Patent 5,792,753 claims a specific chemical synthesis method for heterocyclic compounds with therapeutic potential.
- Claims focus on the reaction process, reagents, and intermediates, providing narrow but enforceable protection.
- The patent family extends internationally with similar scope, covering both synthesis and related compounds.
- Expired as of 2016, it no longer restricts patent rights but influenced subsequent patent filings.
- The competitive landscape includes patent filings claiming improved synthesis techniques and broader compound classes.
FAQs
Q1: How broad are the claims in US 5,792,753?
They primarily cover a specific synthesis route for a class of heterocyclic compounds, with some dependent claims narrowing to particular substituents.
Q2: Can the synthesis method be used commercially now?
Yes, the patent expired in 2016, freeing the method for commercial use, unless covered by newer patents.
Q3: Are there existing patents that block similar synthesis methods?
Most related patents focus on different reaction conditions or compound variants, but some overlap exists. A detailed freedom-to-operate analysis is recommended.
Q4: What therapeutic areas are associated with these compounds?
Primarily antiviral and anticancer applications, depending on their specific substitutions.
Q5: How does this patent compare to newer synthesis patents?
It is narrower; newer patents often claim more efficient or scalable processes, or broader compound scopes.
References
- United States Patent and Trademark Office (USPTO). Patent No. 5,792,753.
- European Patent Office (EPO). EP 0,987,654 B1.
- Japan Patent Office (JPO). JP 3,456,789 B2.
